These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 25910299)
1. A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis. Yalcin M; Akarsu M; Celik A; Sagol O; Tunali S; Ertener O; Bengi G; Akpinar H Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():167-75. PubMed ID: 25910299 [TBL] [Abstract][Full Text] [Related]
2. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Schramm C; Schneider A; Marx A; Lohse AW Z Gastroenterol; 2008 Dec; 46(12):1369-71. PubMed ID: 19053005 [TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Thomsen KL; Hebbard L; Glavind E; Clouston A; Vilstrup H; George J; Grønbæk H Liver Int; 2014 Nov; 34(10):1584-92. PubMed ID: 24674765 [TBL] [Abstract][Full Text] [Related]
6. Role of modulation of vascular endothelial growth factor and tumor necrosis factor-alpha in gastric ulcer healing in diabetic rats. Baraka AM; Guemei A; Gawad HA Biochem Pharmacol; 2010 Jun; 79(11):1634-9. PubMed ID: 20144589 [TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848 [TBL] [Abstract][Full Text] [Related]
8. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. El-Haggar SM; Mostafa TM Hepatol Int; 2015 Jul; 9(3):471-9. PubMed ID: 25956613 [TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Satapathy SK; Garg S; Chauhan R; Sakhuja P; Malhotra V; Sharma BC; Sarin SK Am J Gastroenterol; 2004 Oct; 99(10):1946-52. PubMed ID: 15447754 [TBL] [Abstract][Full Text] [Related]
10. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ; Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819 [TBL] [Abstract][Full Text] [Related]
11. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840 [TBL] [Abstract][Full Text] [Related]
13. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Chen YM; Ng YY; Lin SL; Chiang WC; Lan HY; Tsai TJ Nephrol Dial Transplant; 2004 May; 19(5):1106-15. PubMed ID: 14993492 [TBL] [Abstract][Full Text] [Related]
14. Pentoxifylline in the management of metabolic syndrome and chronic hepatitis C. Metwally AH Med Hypotheses; 2014 Dec; 83(6):832-4. PubMed ID: 25468788 [TBL] [Abstract][Full Text] [Related]
15. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital]. Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230 [TBL] [Abstract][Full Text] [Related]
16. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. Aghazadeh S; Amini R; Yazdanparast R; Ghaffari SH Exp Toxicol Pathol; 2011 Sep; 63(6):569-74. PubMed ID: 20471811 [TBL] [Abstract][Full Text] [Related]
17. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. Zeng T; Zhang CL; Zhao XL; Xie KQ Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):646-53. PubMed ID: 24743504 [TBL] [Abstract][Full Text] [Related]
18. Pentoxifylline and its association with kaempferol improve NASH-associated manifestation in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms. Hamouda AO; Abdel-Hamed AR; Abo-Elmatty DM; Khedr NF; Ghattas MH Eur Rev Med Pharmacol Sci; 2022 Dec; 26(23):8644-8659. PubMed ID: 36524484 [TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride. de Moura FJ; Leal PP; de Souza Furtado R; Muniz-Junqueira MI; Veiga JP Toxicology; 2008 Jan; 243(1-2):66-74. PubMed ID: 18022309 [TBL] [Abstract][Full Text] [Related]